By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 164.42 |
| Change Today | $ -4.15 |
| % Change | -2.46 % |
| 52 Week High | $187.62 |
| 52 Week Low | $118.84 |
| Volume | 1,816,538 |
| Shares Issued | 145.80m |
| Market Cap | $23,972m |
| RiskGrade | 259 |
| Time | Volume / Share Price |
| 15:59 | 110 @ $164.42 |
| 15:59 | 100 @ $164.42 |
| 15:59 | 100 @ $164.39 |
| 15:59 | 102 @ $164.35 |
| 15:59 | 100 @ $164.39 |
You are here: research